The latest study data on INNOVENT BIO (01801.HK) +0.850 (+1.176%) Short selling $121.31M; Ratio 6.982% 's PD-1/IL-2alpha-bias bispecific antibody fusion protein product, IBI363, and recombinant humanized anti-CLDN18.2 ADC, IBI343, are encouraging, JPMorgan published a research report saying. The broker believed that both drugs have significant potential, leading to an upgrade in potential China sales forecasts and the addition of potential US market sales forecasts for these two candidate drugs, based on the expectation that INNOVENT BIO may license these assets overseas or initiate global development independently.Related NewsBOCI Elevates INNOVENT BIO (01801.HK) TP to $82, Keeps Rating at BuyJPMorgan currently estimated that IBI363 could achieve sales of RMB2.5 billion in China and nearly US$1 billion in the US, while IBI343's sales in China are forecasted to reach RMB1.5 billion, with potential US sales of US$250 million. Accordingly, the broker elevated its target price from $55 to $74, and continued to list INNOVENT BIO as its top pick among biotech companies. JPMorgan also lifted its 2029-2033 total sales forecasts for the Company by 7-45%, with rating kept at Overweight. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)